Adisseo in the news

Adisseo appoints Li Bo, former chairman of its majority shareholder China National Bluestar, as its new chairman and CEO to lead its global strategy and executive team, focusing on methionine, Specialties, and vitamins.

Adisseo appointed Li Bo as its new Chairman and CEO, effective November 1, 2026, succeeding Dr. Hao Zhigang.

Adisseo has appointed Li Bo as its new chairman and CEO, effective November 1, succeeding Dr. Hao Zhigang.

Li Bo has been appointed Chairman and CEO of Adisseo, effective November 1, 2026, succeeding Dr. Hao Zhigang.

Bluestar Adisseo's Deputy General Manager received a penalty from the Chinese Securities Watchdog, while the document also outlines various financial and ESG rating systems for companies.

Bluestar Adisseo's deputy general manager was sanctioned by the Chinese financial regulator, with the document also describing various financial and ESG ratings.

The Deputy General Manager of Bluestar Adisseo was sanctioned by the Chinese financial regulator, and the document also details various financial and ESG rating methodologies.

Bluestar Adisseo's half-year net profit increased by 22.25% year-over-year.

Bluestar Adisseo's H1 net profit saw a 22.25% increase year-over-year.

The president of Bluestar Adisseo has resigned, and this document details various financial and ESG composite ratings for investors.

The document describes various financial rating methodologies for evaluating companies, including investor, trader, global, quality, and ESG scores, and briefly mentions the resignation of Bluestar Adisseo's Chair.

Bluestar Adisseo Co. Class A's revenue last year reached 17.23 billion CNY, with Functional Products and Europe being the top segment and region respectively.

Calysta is hiring a new CEO and seeking new capital after its joint venture partner Adisseo ended financial support for their microbial protein production facility in China due to financial difficulties and production scale-up challenges.

Adisseo is ceasing financial support for its Calysseo joint venture due to unsuccessful efforts to secure external financing and ongoing operational challenges at Calysseo's production facility.

Adisseo is ceasing financial support for its Calysseo joint venture due to unsuccessful efforts to secure external financing for the struggling aquafeed protein producer.

This document tracks SSE:600299 financial statements and analyst forecasts for performance evaluation.

Bluestar Adisseo (600299) shows significant recent stock price declines despite stable net income growth and positive analyst price targets.

The document provides an enterprise value to EBITDA forward for Bluestar Adisseo Co. Class A, with data from FactSet Research Systems Inc.